# US 2013/0260376 A1 · Prediction of and Monitoring Cancer Therapy Response Based on Gene Expression Profiling

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0260376 A1
- Document ID: US20130260376A1
- Status: Published application
- Kind: A1
- Application number: 13/813,150
- Filed: 2011-08-02
- Published: 2013-10-03
- Earliest claimed: 2010-08-02
- Assignees: Whitehead Institute for Biomedical Research; The Broad Institute, Inc.
- Inventors: Piyush Gupta; Tamer T. Onder; Eric S. Lander; Robert Weinberg; Sendurai Mani
- Web page: https://patentgrep.com/patent/US20130260376A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/136: Screening for pharmacological compounds
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The invention utilizes gene expression profiles in methods of predicting the likelihood that a patient's cancer will respond to standard-of-care therapy. Also provided are methods of identifying therapeutic agents that target cancer stem cells or epithelial cancers that have undergone an epithelial to mesenchymal transition using such gene expression profiles.

## Claims

### Claim 1

A method of predicting the likelihood that a patient's epithelial cancer will respond to a standard-of-care therapy, following surgical removal of the primary tumor, comprising determining the expression level in cancer of genes in Tables 1 or 2, wherein the overexpression of genes in Table 1 indicates an increased likelihood that the tumor will be resistant to the standard-of-care therapy and overexpression of genes in Table 2 indicates an increased likelihood that the tumor will be sensitive to the standard-of-care therapy.

### Claim 2 (depends on 1)

The method of claim 1, wherein the overexpression of genes in Table 1 indicates an increased likelihood that the tumor will be resistant to standard-of-care therapy.

### Claim 3 (depends on 2)

The method of claim 2 wherein the overexpression of genes in Table 1 indicates an increased likelihood that the tumor will be resistant to paclitaxel.

### Claim 4 (depends on 1)

The method of claim 1, wherein the standard-of-care therapy is a kinase-targeted therapy, such as EGFR-inhibition.

### Claim 5 (depends on 1)

The method of claim 1, wherein the standard-of-care therapy is a radiation.

### Claim 6 (depends on 1)

The method of claim 1, wherein the standard-of-care therapy is a hormonal therapy.

### Claim 7 (depends on 1, 3, 4, 5, 6)

The method of claim 1, wherein the therapy is a combination of therapies indicated in claims 3-6.

### Claim 8 (depends on 1)

The method of claim 1, wherein the expression level of the genes assayed constitutes any subset of the genes in Table 1 or Table 2.

### Claim 9 (depends on 8)

The method of claim 8, wherein the subset of genes is one for which a statistical test demonstrates that the genes in the subset are differentially expressed in populations treated with a cancer therapy at a level of significance less than 0.1, relative to an appropriate control population.

### Claim 10 (depends on 9)

The method of claim 9, wherein the cancer therapy is selected from the group consisting of salinomycin treatment and paclitaxel treatment.

### Claim 11 (depends on 8)

The method of claim 8, wherein the subset of genes comprises 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 of the genes in Table 1 or Table 2.

### Claim 12 (depends on 1)

The method of claim 1, wherein the overexpression of genes in Table 1 indicates an increased likelihood that the tumor will be sensitive to therapeutic agents that are toxic to cancer cells resistant to standard-of-care therapies.

### Claim 13 (depends on 1)

The method of claim 1, wherein the overexpression of genes in Table 1 indicates an increased likelihood that the tumor will be sensitive to therapeutic agents that are toxic to cancer stem cells or to therapeutic agents that target invasive, metastatic, or invasive and metastatic cancer cells.

### Claim 14 (depends on 1)

The method of claim 1, wherein the overexpression of genes in Table 1 indicates an increased likelihood that the tumor will be sensitive to therapeutic agents that are toxic to cancer cells that have undergone an epithelial-to-mesenchymal transition.

### Claim 15 (depends on 1)

The method of claim 1, wherein the overexpression of genes in Table 1 indicates an increased likelihood that the tumor will be sensitive to salinomycin.

### Claim 16

A method of predicting the likelihood that a patient's epithelial cancer will respond to standard-of-care therapy, following surgical removal of the primary tumor, comprising determining the expression level in cancer of genes in Table 2.

### Claim 17 (depends on 16)

The method of claim 16, wherein the reduced expression of genes in Table 2 indicates an increased likelihood that the tumor will be resistant to standard-of-care therapy.

### Claim 18 (depends on 16)

The method of claim 16, wherein the standard-of-care therapy is a kinase-targeted therapy, such as EGFR-inhibition.

### Claim 19 (depends on 16)

The method of claim 16, wherein the standard-of-care therapy is a radiation therapy.

### Claim 20 (depends on 16)

The method of claim 16, wherein the standard-of-care therapy is a hormonal therapy.

### Claim 21 (depends on 16)

The method of claim 16, wherein the standard-of-care therapy is paclitaxel.

### Claim 22 (depends on 16, 17, 18, 19, 20, 21)

The method of claim 16, wherein the standard-of-care therapy is a combination of therapies indicated in claims 17-21.

### Claim 23 (depends on 16)

The method of claim 16, wherein the expression level of the genes assayed constitutes any subset of the genes in Table 2.

### Claim 24 (depends on 23)

The method of claim 23, wherein the subset of genes is one for which a statistical test demonstrates that the genes in the subset are differentially expressed in populations treated with a cancer therapy at a level of significance less than 0.1, relative to an appropriate control population.

### Claim 25 (depends on 24)

The method of claim 24, wherein the cancer therapy is selected from the group consisting of salinomycin treatment and paclitaxel treatment.

### Claim 26 (depends on 23)

The method of claim 23, wherein the subset of genes comprises 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 of the genes in Table 2.

### Claim 27 (depends on 16)

The method of claim 16, wherein the reduced expression of genes in Table 2 indicates an increased likelihood that the tumor will be sensitive to therapeutic agents that are toxic to cancer cells resistant to standard-of-care therapies.

### Claim 28 (depends on 16)

The method of claim 16, wherein the reduced expression of genes in Table 2 indicates an increased likelihood that the tumor will be sensitive to therapeutic agents that are toxic to cancer stem cells or to therapeutic agents that target invasive, metastatic, or invasive and metastatic cancer cells.

### Claim 29 (depends on 16)

The method of claim 16, wherein the reduced expression of genes in Table 2 indicates an increased likelihood that the tumor will be sensitive to therapeutic agents that are toxic to cancer cells that have undergone an epithelial-to-mesenchymal transition.

### Claim 30 (depends on 16)

The method of claim 16, wherein the reduced expression of genes in Table 2 indicates an increased likelihood that the tumor will be sensitive to salinomycin.

### Claim 31

A method of identifying therapeutic agents that target cancer stem cells or epithelial cancers that have undergone an epithelial to mesenchymal transition comprising screening candidate agents to identify those that increase the levels of expression of the genes in Table 2, wherein an increase in the expression of genes in Table 2 indicates that the candidate agent targets cancer stem cells or epithelial cancers that have undergone an epithelial to mesenchymal transition.

### Claim 32 (depends on 31)

The method of claim 31, wherein any subset of genes in Table 2 is evaluated for its expression levels.

### Claim 33 (depends on 32)

The method of claim 32, wherein the subset of genes is one for which a statistical test demonstrates that the genes in the subset are differentially expressed in populations treated with a cancer therapy at a level of significance less than 0.1, relative to an appropriate control population.

### Claim 34 (depends on 33)

The method of claim 33, wherein the cancer therapy is selected from the group consisting of salinomycin treatment and paclitaxel treatment.

### Claim 35 (depends on 32)

The method of claim 32, wherein the subset of genes comprises 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 of the genes in Table 2.

### Claim 36

A method of identifying therapeutic agents that target cancer stem cells or epithelial cancers that have undergone an epithelial to mesenchymal transition comprising screening candidate agents to identify those that decrease the levels of expression of the genes in Table 1, wherein a decrease in the expression of genes in Table 1 indicates that the candidate agent targets cancer stem cells or epithelial cancers that have undergone an epithelial to mesenchymal transition.

### Claim 37 (depends on 36)

The method of claim 36, wherein any subset of genes in Table 1 is evaluated for its expression levels.

### Claim 38 (depends on 37)

The method of claim 37, wherein the subset of genes whose expression is evaluated is one for which a statistical test demonstrates that the genes in the subset are differentially expressed in populations treated with a cancer therapy at a level of significance less than 0.1, relative to an appropriate control population.

### Claim 39 (depends on 38)

The method of claim 38, wherein the cancer therapy is selected from the group consisting of salinomycin treatment and paclitaxel treatment.

### Claim 40 (depends on 37)

The method of claim 37, wherein the subset of genes comprises 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 of the genes in Table 1.

### Claim 41

A method of predicting the likelihood that a patient's epithelial cancer will respond to therapy, following surgical removal of the primary tumor, comprising determining the expression level in cancer of genes in Table 1, wherein the overexpression of genes in Table 1 indicates an increased likelihood that the tumor will be sensitive to therapy with salinomycin or other CSS agents.

### Claim 42

A method of predicting the likelihood that a patient's epithelial cancer will respond to therapy, following surgical removal of the primary tumor, comprising determining the expression level in cancer of genes in Table 1, wherein the overexpression of genes in Table 1 indicates an increased likelihood that the tumor will be resistant to standard-of-care therapy.

### Claim 43 (depends on 42)

The method of claim 42 wherein the standard-of-care therapy is paclitaxel.

### Claim 44 (depends on 41)

The method of claim 41, wherein any subset of genes in Table 1 is evaluated for its expression levels.

### Claim 45 (depends on 44)

The method of claim 44, wherein the subset of the genes whose expression is evaluated is one for which a statistical test demonstrates that the genes in the subset are differentially expressed in populations treated with a cancer therapy at a level of significance less than 0.1, relative to an appropriate control population.

### Claim 46 (depends on 45)

The method of claim 45, wherein the cancer therapy is selected from the group consisting of salinomycin treatment and paclitaxel treatment.

### Claim 47 (depends on 42)

The method of claim 42, wherein the subset of genes comprises 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 of the genes in Table 1.

### Claim 48 (depends on 1)

The method of claim 1, further comprising summarizing the data obtained by the determination of said gene expression levels.

### Claim 49 (depends on 48)

The method of claim 48, wherein said summarizing includes prediction of the likelihood of long term survival of said patient without recurrence of the cancer following surgical removal of the primary tumor.

### Claim 50 (depends on 48)

The method of claim 48, wherein said summarizing includes recommendation for a treatment modality of said patient.

### Claim 51

A kit comprising in one or more containers, at least one detectably labeled reagent that specifically recognizes one or more of the genes in Table 1 or Table 2.

### Claim 52 (depends on 51)

The kit of claim 51, wherein the level of expression of the one or more genes in Table 1 or Table 2 in cancer is determined.

### Claim 53 (depends on 51)

The kit of claim 51, wherein the kit is used to generate a biomarker profile of an epithelial cancer.

### Claim 54 (depends on 51)

The kit of claim 51, wherein the kit further comprises at least one pharmaceutical excipient, diluents, adjuvant, or any combination thereof.

### Claim 55 (depends on 1)

The method of claim 1, wherein the RNA expression levels are indirectly evaluated by determining protein expression levels of the corresponding gene products.

### Claim 56 (depends on 55)

The method of claim 55, wherein the RNA expression levels are indirectly evaluated by determining chromatin states of the corresponding genes.

### Claim 57 (depends on 55)

The method of claim 55 wherein said RNA is isolated from a fixed, wax-embedded breast cancer tissue specimen of said patient.

### Claim 58 (depends on 55)

The method of claim 55, wherein said RNA is fragmented RNA.

### Claim 59 (depends on 55)

The method of claim 55, wherein said RNA is isolated from a fine needle biopsy sample.

### Claim 60 (depends on 1)

The method of claim 1, wherein the cancer is an epithelial cancer.

### Claim 61 (depends on 1)

The method of claim 1, wherein the cancer is a lung, breast, prostate, gastric, colon, pancreatic, brain, or melanoma cancer.
